Multiple Myeloma Patient Registry

Inclusion Criteria:

• Must sign, and/or their legally acceptable representative where applicable mustsign, a participation agreement/informed consent form (ICF) allowing data collectionand source data verification in accordance with local requirements

• Have a diagnosis of relapsed MM [according to 2014 International Myeloma WorkingGroup (IMWG) criteria] with 1 to 3 prior lines of therapy. (An induction regimenfollowed by autologous stem cell transplantation and single-agent maintenancetherapy will be considered a single line of therapy.)

• Participants must have initiated a new line of induction therapy that includes aproteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) within 90 days priorto enrollment. A short course of corticosteroids is allowed prior to initiating thenew line of induction therapy

• Must be willing and able to complete the protocol-required patient-reported outcome (PROs)

Exclusion Criteria:

• Participant has plasma cell leukemia [greater than (>) 2.0 * 10^9 per liter]circulating plasma cells by standard differential), Waldenstrom's macroglobulinemia,POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and/or skinchanges), or amyloid light-chain amyloidosis

• Participant has a life expectancy of less than 6 months

• At the time of screening, participant is enrolled in an interventional clinicaltrial for MM using an anti-neoplastic agent that is not currently approved by theUnited States (US) Food and Drug Administration (FDA)